X0202 SCHEDULE 13G/A 0002005369 XXXXXXXX LIVE 5 Common Stock $0.001 par value per share 03/31/2026 0001707502 Solid Biosciences Inc. 83422E204 500 Rutherford Avenue 3rd Floor Charlestown MA 02129 Rule 13d-1(c) Invus Public Equities, L.P. D0 8696431.00 0.00 8696431.00 0.00 8696431.00 Y 8.7 PN See Item 4 for a description of the information reported in rows (5), (7), (9) and (11). Invus Public Equities Advisors, LLC DE 8696431.00 0.00 8696431.00 0.00 8696431.00 Y 8.7 OO See Item 4 for a description of the information reported in rows (5), (7), (9) and (11). Invus Global Management, LLC DE 8696431.00 0.00 8696431.00 0.00 8696431.00 Y 8.7 OO See Item 4 for a description of the information reported in rows (5), (7), (9) and (11). Siren, L.L.C. DE 8696431.00 0.00 8696431.00 0.00 8696431.00 Y 8.7 OO See Item 4 for a description of the information reported in rows (5), (7), (9) and (11). Avicenna Life Sci Master Fund LP E9 1370251.00 0.00 1370251.00 0.00 1370251.00 Y 1.4 PN See Item 4 for a description of the information reported in rows (5), (7), (9) and (11). Avicenna Life Sci Master GP LLC DE 1370251.00 0.00 1370251.00 0.00 1370251.00 Y 1.4 OO See Item 4 for a description of the information reported in rows (5), (7), (9) and (11). Ulys, L.L.C. DE 1370251.00 0.00 1370251.00 0.00 1370251.00 Y 1.4 OO See Item 4 for a description of the information reported in rows (5), (7), (9) and (11). Raymond Debbane R1 10066682.00 0.00 10066682.00 0.00 10066682.00 Y 9.99 IN See Item 4 for a description of the information reported in rows (5), (7), (9) and (11). Solid Biosciences Inc. 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129 See Item 2(c) below. See Item 2(c) below. (i) Invus Public Equities, L.P. ("Invus Public Equities") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Bermuda limited partnership (ii) Invus Public Equities Advisors, LLC ("Invus PE Advisors") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iii) Invus Global Management, LLC ("Global Management") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iv) Siren, L.L.C. ("Siren") c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (v) Avicenna Life Sci Master Fund LP ("Avicenna Fund") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Cayman Islands limited partnership (vi) Avicenna Life Sci Master GP LLC ("Avicenna GP") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (vii) Ulys, L.L.C. ("Ulys") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (viii) Mr. Raymond Debbane 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Panama The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Y As of March 31, 2026, Invus Public Equities directly held 6,643,607 shares of common stock $0.001 par value per share (the "Shares") of Solid Biosciences Inc. (the "Issuer") and 3,821,188 Issuer Pre-Funded Warrants exercisable for Shares on a one-for-one basis (the "Warrants"), and Avicenna Fund directly held 1,046,798 Shares of the Issuer and 456,886 Warrants. The Warrants are subject to the Beneficial Ownership Limitation described below. Each of Invus Public Equities' and Avicenna Fund's Warrants has an exercise price of $0.001 per Share and no expiration date. As of March 31, 2026, due to the Beneficial Ownership Limitation, the Reporting Persons collectively beneficially owned 10,066,682 Shares, consisting of an aggregate of 7,690,405 Shares and 2,376,277 Warrants, representing 9.99% of the issued and outstanding Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares directly held by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own. Each of Invus Public Equities and Avicenna Fund is prohibited from exercising the Warrants if, as a result of such exercise, it, together with its affiliates and certain other persons for whom beneficial ownership would be aggregated, would beneficially own more than 9.99% of the total number of Shares then issued and outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation"), which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. Reporting Persons disclaim beneficial ownership of any Shares the issuance of which would violate such Beneficial Ownership Limitation. As of March 31, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on (i) 98,391,314 Shares outstanding as of March 16, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19, 2026, plus (ii) 2,376,277 Shares issuable upon exercise of certain of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of Shares that could be issued upon exercise of the Warrants as of the date hereof. See each cover page hereof. See each cover page hereof. See each cover page hereof. See each cover page hereof. Y Y Y Y Y N Each of the Reporting Persons hereby makes the following certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Invus Public Equities, L.P. /s/ Raymond Debbane 05/05/2026 Invus Public Equities Advisors, LLC /s/ Raymond Debbane 05/05/2026 Invus Global Management, LLC /s/ Raymond Debbane 05/05/2026 Siren, L.L.C. /s/ Raymond Debbane 05/05/2026 Avicenna Life Sci Master Fund LP /s/ Raymond Debbane 05/05/2026 Avicenna Life Sci Master GP LLC /s/ Raymond Debbane 05/05/2026 Ulys, L.L.C. /s/ Raymond Debbane 05/05/2026 Raymond Debbane /s/ Raymond Debbane 05/05/2026